Literature DB >> 25649924

Serum lipoprotein (a) concentrations are inversely associated with T2D, prediabetes, and insulin resistance in a middle-aged and elderly Chinese population.

Lin Ding1, An Song2, Meng Dai1, Min Xu1, Wanwan Sun1, Baihui Xu1, Jichao Sun1, Tiange Wang1, Yu Xu1, Jieli Lu1, Weiqing Wang1, Yufang Bi1, Guang Ning1.   

Abstract

Lipoprotein (a) [Lp(a)], an LDL-like particle, has been proposed as a causal risk factor for CVD among general populations. Meanwhile, both serum Lp(a) and diabetes increase the risk of CVD. However, the relationship between serum Lp(a) and T2D is poorly characterized, especially in the Asian population. Therefore, we conducted a cross-sectional study in 10,122 participants aged 40 years or older in Jiading District, Shanghai, China. Our study found that the prevalence of T2D was decreased from 20.9% to 15.0% from the lowest quartile to the highest quartile of serum Lp(a) concentrations (P for trend <0.0001). Logistic regression analyses showed that the odds ratios and 95% confidence intervals of prevalent T2D for quartiles 2-4 versus quartile 1 were 0.86 (0.73-1.01), 0.88 (0.75-1.04), and 0.76 (0.64-0.90) (P for trend = 0.0002), after adjustment for traditional confounding factors. Moreover, the risks for prevalent prediabetes, insulin resistance, and hyperinsulinemia were also decreased from the lowest to the top quartile. This inverse association between serum Lp(a) and T2D was not appreciably changed after we adjusted hypoglycemic medications or excluded the subjects with hypoglycemic and/or lipid-lowering agents and/or a history of self-reported CVD.
Copyright © 2015 by the American Society for Biochemistry and Molecular Biology, Inc.

Entities:  

Keywords:  cardiovascular risk; epidemiology; lipid; type 2 diabetes

Mesh:

Substances:

Year:  2015        PMID: 25649924      PMCID: PMC4373748          DOI: 10.1194/jlr.P049015

Source DB:  PubMed          Journal:  J Lipid Res        ISSN: 0022-2275            Impact factor:   5.922


  32 in total

1.  Metformin and lipoprotein(a) levels.

Authors:  J A Kiayias; E D Vlachou; E L Papadodima
Journal:  Diabetes Care       Date:  1999-05       Impact factor: 19.112

2.  Metformin lowers lipoprotein(a) levels.

Authors:  D S Bell; F Ovalle
Journal:  Diabetes Care       Date:  1998-11       Impact factor: 19.112

3.  Fifty years of lipoprotein(a) -- the magical mystery tour continues.

Authors:  B Angelin
Journal:  J Intern Med       Date:  2013-01       Impact factor: 8.989

Review 4.  Lipoprotein(a): resurrected by genetics.

Authors:  F Kronenberg; G Utermann
Journal:  J Intern Med       Date:  2012-11-12       Impact factor: 8.989

5.  Nonalcoholic fatty liver disease is associated with atherosclerosis in middle-aged and elderly Chinese.

Authors:  Yun Huang; Yufang Bi; Min Xu; Zhimin Ma; Yu Xu; Tiange Wang; Mian Li; Yu Liu; Jieli Lu; Yuhong Chen; Fei Huang; Baihui Xu; Jie Zhang; Weiqing Wang; Xiaoying Li; Guang Ning
Journal:  Arterioscler Thromb Vasc Biol       Date:  2012-07-19       Impact factor: 8.311

6.  Farnesoid X receptor represses hepatic human APOA gene expression.

Authors:  Indumathi Chennamsetty; Thierry Claudel; Karam M Kostner; Anna Baghdasaryan; Dagmar Kratky; Sanja Levak-Frank; Sasa Frank; Frank J Gonzalez; Michael Trauner; Gert M Kostner
Journal:  J Clin Invest       Date:  2011-08-01       Impact factor: 14.808

7.  Association between nonalcoholic fatty liver disease (NAFLD) and osteoporotic fracture in middle-aged and elderly Chinese.

Authors:  Mian Li; Yu Xu; Min Xu; Lingying Ma; Tiange Wang; Yu Liu; Meng Dai; Yuhong Chen; Jieli Lu; Jianmin Liu; Yufang Bi; Guang Ning
Journal:  J Clin Endocrinol Metab       Date:  2012-03-30       Impact factor: 5.958

8.  Lipoprotein(a) and risk of type 2 diabetes.

Authors:  Samia Mora; Pia R Kamstrup; Nader Rifai; Børge G Nordestgaard; Julie E Buring; Paul M Ridker
Journal:  Clin Chem       Date:  2010-05-28       Impact factor: 8.327

9.  Insulin suppresses apolipoprotein(a) synthesis by primary cultures of cynomolgus monkey hepatocytes.

Authors:  D M Neele; E C de Wit; H M Princen
Journal:  Diabetologia       Date:  1999-01       Impact factor: 10.122

10.  Reliability and validity of the International Physical Activity Questionnaire (IPAQ) in elderly adults: the Fujiwara-kyo Study.

Authors:  Kimiko Tomioka; Junko Iwamoto; Keigo Saeki; Nozomi Okamoto
Journal:  J Epidemiol       Date:  2011-09-24       Impact factor: 3.211

View more
  23 in total

Review 1.  Structure, function, and genetics of lipoprotein (a).

Authors:  Konrad Schmidt; Asma Noureen; Florian Kronenberg; Gerd Utermann
Journal:  J Lipid Res       Date:  2016-04-13       Impact factor: 5.922

Review 2.  Lipoprotein (a) as a cause of cardiovascular disease: insights from epidemiology, genetics, and biology.

Authors:  Børge G Nordestgaard; Anne Langsted
Journal:  J Lipid Res       Date:  2016-09-27       Impact factor: 5.922

3.  LPA kringle IV type 2 is associated with type 2 diabetes in a Chinese population with very high cardiovascular risk.

Authors:  Di-Li-Da-Er Mu-Han-Ha-Li 迪丽达尔 木汗哈力; Tian-Yu Zhai 翟天羽; Yan Ling 凌雁; Xin Gao 高鑫
Journal:  J Lipid Res       Date:  2018-03-06       Impact factor: 5.922

4.  In search of a physiological function of lipoprotein(a): causality of elevated Lp(a) levels and reduced incidence of type 2 diabetes.

Authors:  Sotirios Tsimikas
Journal:  J Lipid Res       Date:  2018-04-02       Impact factor: 5.922

5.  Analysis of the association between plasma PCSK9 and Lp(a) in Han Chinese.

Authors:  S-H Yang; S Li; Y Zhang; R-X Xu; C-G Zhu; Y-L Guo; N-Q Wu; P Qing; Y Gao; C-J Cui; Q Dong; J Sun; J-J Li
Journal:  J Endocrinol Invest       Date:  2016-02-19       Impact factor: 4.256

Review 6.  Lipoprotein (a): impact by ethnicity and environmental and medical conditions.

Authors:  Byambaa Enkhmaa; Erdembileg Anuurad; Lars Berglund
Journal:  J Lipid Res       Date:  2015-12-04       Impact factor: 5.922

Review 7.  Advances in lipid-lowering therapy through gene-silencing technologies.

Authors:  Børge G Nordestgaard; Stephen J Nicholls; Anne Langsted; Kausik K Ray; Anne Tybjærg-Hansen
Journal:  Nat Rev Cardiol       Date:  2018-02-08       Impact factor: 32.419

8.  Lipoprotein (a) and coronary artery calcification: prospective study assessing interactions with other risk factors.

Authors:  Kwok Leung Ong; Robyn L McClelland; Matthew A Allison; Mary Cushman; Parveen K Garg; Michael Y Tsai; Kerry-Anne Rye; Fatiha Tabet
Journal:  Metabolism       Date:  2021-01-07       Impact factor: 8.694

Review 9.  Human Genetics and the Causal Role of Lipoprotein(a) for Various Diseases.

Authors:  Florian Kronenberg
Journal:  Cardiovasc Drugs Ther       Date:  2016-02       Impact factor: 3.727

10.  Lipoprotein(a): a not-so-well-known risk factor for the development of cardiovascular disease in patients with type 2 diabetes mellitus.

Authors:  Min Kyong Moon
Journal:  Korean J Intern Med       Date:  2016-11-01       Impact factor: 2.884

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.